Review anchor
Sphingosine-1-phosphate receptor 1
SINGLE PROTEIN · Canis lupus familiaris
As of 2026-09-13
Evidence Snapshot
Sphingosine-1-phosphate receptor 1
CHEMBL3559680
SINGLE PROTEIN
Canis lupus familiaris
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Sphingosine-1-phosphate receptor 1 as ChEMBL target CHEMBL3559680, mapped to UniProt W5VNF7. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3559680
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
W5VNF7
Sphingosine 1-phosphate receptor 1
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Sphingosine-1-phosphate receptor 1 matters
Sphingosine-1-phosphate receptor 1 is reviewed as Sphingosine 1-phosphate receptor 1 (UniProt W5VNF7); the current evidence base includes 1 approved drug, 4 compounds, and 5 assays, with lead potency reaching pChEMBL 10.4.
Protein context
Sphingosine 1-phosphate receptor 1
Sphingosine 1-phosphate receptor 1 Sequence length is 381 aa.
Review this target as Sphingosine-1-phosphate receptor 1, mapped to UniProt W5VNF7. ChEMBL maps the protein component as Sphingosine 1-phosphate receptor 1. Sequence length is 381 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt W5VNF7
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 1 approved drug, 4 compounds, and 5 assays for this target. The dominant activity type is EC50. CHEMBL3403619 is the current potency anchor at pChEMBL 10.4.
Use CHEMBL3403619 as the tractability anchor when discussing potency (pChEMBL 10.4).
Activity source · ChEMBL 36 via Core Engine
1 approved
pChEMBL 10.4
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Sphingosine-1-phosphate receptor 1 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt W5VNF7, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
4
Total Compounds
5
Total Assays
1
Approved Drugs
EC50: 4.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3403619
|
10.4 | EC50 | — |
|
|
No preferred name
CHEMBL3359522
|
10.3 | EC50 | — |
|
|
No preferred name
CHEMBL3359523
|
10.3 | EC50 | — |
|
|
No preferred name
CHEMBL3358920
|
9.5 | EC50 | Approved |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ETRASIMOD
CHEMBL3358920
|
2023 |
Source Header